Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases and conditions using its proprietary hydrogel platform technology.

Ocular Therapeutix

OTX at ARVO 2014

ReSure Sealant

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.

Sparta Group

Versant Ventures

Ascension Ventures

Polaris Venture Capital

Baxter International

Dan Burgess

SV Health Investors

Polaris Partners

Ocular Therapeutix, Inc.

We're pleased to announce that the first subjects in our Phase 3 SOL-1 clinical trial of #AXPAXLI in Wet AMD have been screened. Learn more here: https://ow.ly/WlsM50QAN3R.

#OCUTX #WETAMD

July is UV Safety Month. Don't forget that it's not just your skin that needs protection from the sun - your eyes do too! As you enjoy time outside this summer, remember to wear UV-blocking sunglasses and hats to help prevent damage to your eyes.

#OCUTX #UVSAFETYMONTH

Happy Fourth of July! We hope you have a great day full of fun with family and friends! 

#OCUTX #FourthofJuly

Join the Ocular Therapeutix team!
#NOWHIRING #SALES #OCUTX

Click here to view the full job description:
https://ow.ly/Y2lo50SuQpz

Click here for a full list of open positions:
https://ow.ly/POa450SuQpw

Please join us in welcoming some of our recent new hires! We're so excited to have you on the team! 

#OCUTX #NEWHIRES

Are you attending the Northwestern Ophthalmology and Vision Research Day in Chicago this Friday? If so, don’t forget to visit our booth to Experience DEXTENZA!

Learn more about DEXTENZA at www.dextenza.com. 

#OCUTX #DEXTENZA

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

COM:OCUTX

Ocular Therapeutix

Last Close

8.56

30/08 20:00

Market Cap

1.11B

Beta: -

Volume Today

597.69K

Avg: -

Analysis Not Available